Previous 10 | Next 10 |
Idera Pharmaceuticals (NASDAQ: IDRA ) : Q2 GAAP EPS of -$0.72 misses by $0.33 . More news on: Idera Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
EXTON, Pa., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera” or the “Company”) (Nasdaq: IDRA) today reported its financial and operational results for the second quarter ended June 30, 2020. “Idera meaningfully advanced its clinica...
Quick Take Checkmate Pharmaceuticals ( CMPI ) intends to raise $75 million from the sale of its common stock stock in an IPO, according to an amended registration statement . The company is advancing a biologic particle treatment for melanomas and head & neck squamous cell carcinomas....
Quick Take Checkmate Pharmaceuticals ( CMPI ) has filed to raise $75 million in an IPO of its common stock, according to an S-1 registration statement . The company is a clinical stage biopharma advancing a drug treatment candidate for melanoma and head & neck cancer. CMPI has produ...
DPW Holdings (NYSEMKT: DPW ) +136% on introducing a new product line of electric vehicle chargers. More news on: DPW Holdings, Inc., Sonnet BioTherapeutics Holdings, Inc., Volt Information Sciences, Inc., Stocks on the move, , Read more ...
Idera Pharmaceuticals (NASDAQ: IDRA ) inks agreements with institutional investors for sale of common shares and warrants to purchase an additional shares of common stock, in a private placement, for gross proceeds of $5.1M (Tranche 1). The combined purchase price is $1.845. More news ...
EXTON, Pa., July 15, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced entering into an agreement with a fund affiliated with institutional investors providing for a private placement exempt from the registration requirements of the Securities Act of 1933, ...
Westwater Resources (NASDAQ: WWR ) +144% on positive independent test results on ULTRA-PMG. More news on: Westwater Resources, Inc., Tenax Therapeutics, Inc., BioHiTech Global, Inc., Stocks on the move, , Read more ...
Thinly traded nano cap Idera Pharmaceuticals (NASDAQ: IDRA ) jumps 17% premarket on increased volume in reaction to preliminary data from an open-label Phase 2 clinical trial, ILLUMINATE-206 , evaluating tilsotolimod, combined with Bristol Myers Squibb's (NYSE: BMY ) Opdivo (n...
EXTON, Pa., June 02, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA; the “Company”) today announced preliminary data from the first 10 patients in the safety cohort of ILLUMINATE-206, a Phase 2, open-label, multi-center study to evaluate tilsotolimod ...
News, Short Squeeze, Breakout and More Instantly...
Idera Pharmaceuticals Inc. Company Name:
IDRA Stock Symbol:
NASDAQ Market:
Idera Pharmaceuticals Inc. Website:
Company completes preferred stock conversion, implements reverse stock split, and regains Nasdaq compliance Company positioned for success with late-stage rare disease portfolio and multiple clinical milestones in 2023 DURHAM, N.C. and EXTON, Pa., Jan. 17, 2023 (GLOBE NEWSWI...
EXTON, Pa. and DURHAM, N.C., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera,” the “Company,” “we,” “us,” or “our”) (Nasdaq: IDRA) today reported its consolidated financial and operational results fo...
Acquisition includes late-stage rare disease portfolio with anticipated 2023 clinical milestones and first potential product approval as early as late 2024 Conference call and webcast today at 5:00 p.m. ET EXTON, Pa. and DURHAM, N.C., Sept. 28, 2022 (GLOBE NEWSWIRE) ...